{"changes":[],"country":"FR","description":"Step Pharma develops first-in-class CTPS1 inhibitors for cancer, led by oral candidate dencatistat for blood cancers and solid tumors. It targets patients with T-cell and B-cell malignancies and other cancers. Its selective CTPS1 inhibition is a novel mechanism distinct from existing therapies.","domain":"step-pharma.com","employees":null,"founded":2014,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":[],"lat":46.235892,"lng":6.028054,"location":"Saint-Genis-Pouilly, France","name":"Step Pharma","rounds":[{"amountQuarantined":false,"amountUsd":2700000,"currency":"EUR","date":"2026-04-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"step-pharma-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"step-pharma.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-pharma.com"},{"fact":"description","publisher":"step-pharma.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-pharma.com"}],"stage":null,"techStack":[],"totalRaisedUsd":102530000,"updatedAt":"2026-05-08"}